The 33% reduction is for the CRABS, approximately. Tysabri is a lot more effective. The problem with actual numbers is that some people naturally have a much higher relapse rate than others. Presumably someone who has a higher natural relapse rate is more likely to have one or more fewer relapses over the next year or two than someone with a lower natural relapse rate. That's why the relative risk reduction makes more sense to me.